Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 7, 2020

Engaging in Recommended Amounts of Exercise Lowers the Risk of Seven Types of Cancer

Author(s):

Beth Fand Incollingo

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.

According to a large new study, doing the recommended levels of leisure-time exercise lowers the risk of seven types of malignancies, including kidney and liver cancers.

The findings came from a pooled analysis of nine prospective studies that included more than 750,000 adults from the U.S., Europe and Australia who had no history of cancer and who self-reported their amounts of exercise.

Among 15 cancer types studied, adherence to recommended exercise amounts lowered the risk of liver cancer by 18% to 27%; of multiple myeloma by 14% to 19%; of non-Hodgkin lymphoma by 11% to 18% in women; of kidney cancer by 11% to 17%; of endometrial cancer by 10% to 18%; of colon cancer by 8% to 14% in men; and of breast cancer by 6% to 10%.

The exercise standards used in the study are recommended in the Physical Activity Guidelines for Americans released by the U.S. Department of Health and Human Services in 2018. The guidelines state that adults should engage in 2.5 to 5.0 hours per week of moderate-intensity activity or 1.25 to 2.5 hours per week of vigorous activity in order to avoid preventable chronic diseases.

The authors of the study defined moderate-intensity activities, such as brisk walking, as those that burn off three to six times as much energy per minute as sitting quietly, or three to six metabolic equivalents (METs). Vigorous-intensity activities were those that were aerobic and burned more than six METs.

Looking separately at moderate-intensity versus vigorous-intensity exercise, the authors found both to be beneficial in preventing colon, breast and kidney cancers but did not collect sufficient data to evaluate each exercise type independently in the other four kinds of cancer.

The researchers also looked at exercise amounts in excess of what was suggested in the guidelines. They determined that doing more than the suggested amount of activity further lowered the risk of colon, breast and endometrial cancers, but did not bring additional benefit in preventing kidney or liver cancers, myeloma or, in women only, non-Hodgkin lymphoma.

This indicates that there is “substantial variation in the underlying biologic mechanisms that link physical activity to different types of cancer,” the authors wrote. “Additional research is needed to better understand these differences.”

The authors embarked on the study to help determine the exact levels of physical activity needed to lower cancer risk. The U.S. Physical Activity Guidelines Advisory Committee had previously evaluated more than 40 reviews and meta-analyses that included multiple studies of this issue, but without determining conclusive answers.

“Our findings provide robust quantitative evidence that supports the new U.S. Physical Activity Guidelines for cancer prevention as well as recommendations that have been promoted by the American Cancer Society, World Cancer Research Fund International, the International Agency for Research on Cancer and the American College of Sports Medicine,” the study’s authors wrote.

They added that "These findings provide direct quantitative support for the levels of activity recommended for cancer prevention and provide actionable evidence for ongoing and future cancer prevention efforts."

Alpa Patel, senior scientific director of epidemiology research at the American Cancer Society, noted that, while "physical activity guidelines have largely been based on their impact on chronic diseases like cardiovascular disease and diabetes,” the study’s findings “provide strong support that these recommended levels are important to cancer prevention, as well."

The analysis was conducted by researchers at the National Cancer Institute, the American Cancer Society, the Harvard T.H. Chan School of Public Health and other institutions. Results were published in the Journal of Clinical Oncology in December 2019.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of man with text.
Photo of Dr. Wenxin (Vincent) Xu
Image of man with text.
Related Content
Advertisement
Image of burt.
August 19th 2025

Jumping Out of Planes, Getting Tattoos and Just Being Me After Cancer

Burt Rosen
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
August 19th 2025

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
August 19th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
cancer horizons podcast logo
August 19th 2025

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes: © stock.adobe.com.
August 19th 2025

Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer

Russ Conroy
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
August 19th 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
Related Content
Advertisement
Image of burt.
August 19th 2025

Jumping Out of Planes, Getting Tattoos and Just Being Me After Cancer

Burt Rosen
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
August 19th 2025

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
August 19th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
cancer horizons podcast logo
August 19th 2025

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes: © stock.adobe.com.
August 19th 2025

Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer

Russ Conroy
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
August 19th 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.